Powered by

Home Top Stories

Pfizer/BioNTech Covid vaccine approved for Use in UK

UK become first country to license a vaccine against Covid-19, opening the way for mass immunisation with the Pfizer/BioNTech vaccine to

By Ground report
New Update
Two suspected terrorists arrested in Delhi

UK become first country across the world to license Pfizer/BioNTech vaccine against Covid-19, opening the way for mass immunisation with the Pfizer/BioNTech vaccine to begin in those most at risk.

UK approval for Pfizer-BioNTech's COVID-19 vaccine to be available nationwide from next week.

Britain has become the first country in the world that has approved the use of vaccines made by the Pfizer-BioNTech Company.

The British regulatory body MHRA has stated that this vaccine from Pfizer-BioNTech gives 95% protection from covid-19 and it is safe to allow its widespread use.

It is being told that within a few days, people who are most at risk will start getting vaccinated. Britain has already placed an order for 40 million doses of this vaccine,

Each person will be given two doses of the vaccine. That is, two crore people can get vaccine right now.

It will be the fastest developed vaccine in the world which took 10 months to make. Usually it takes up to a decade to prepare such a vaccine.

However, experts say that despite the vaccine, people should keep following the rules to prevent infection.

Earlier Initial analysis has shown that the first vaccine made for covid can prevent infection in 90 percent of people. This vaccine is made by the world’s largest pharmaceutical company PFisar and BioNetac. It has been said on behalf of companies that this is ‘great day for science and humanity’.

Companies will make an emergency application to get permission to use the vaccine by the end of this month.

Along with better treatment, the vaccine itself is considered to be the biggest weapon in the fight against the virus.

They can also protect against the restrictions that are due to the corona virus.

The vaccine has so far been tested on 43,500 people in six countries and no concerns have been raised about safety.